Replimune Group (REPL)
(Real Time Quote from BATS)
$7.98 USD
-0.39 (-4.60%)
Updated Jun 17, 2024 10:04 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Replimune Group, Inc. [REPL]
Reports for Purchase
Showing records 161 - 180 ( 193 total )
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 Opdivo Update at SITC is Encouraging, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 Ph 1 Dataset Impressive; Melanoma Program Expanded; Raising PT to $30
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
SITC - Early Data Infectious as Some Tumors Melt
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - SITC 2019 Abstract Title Preview for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP2 Phase 1/2 Trial Initiates Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Positive Early Data in CSCC; Ph 2 Study Initiates
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Initial CSCC data hint that RP1 may be more potent than T-VEC.- Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1''s Addition to Anti-PD-1 mAbs For Anticancer Therapy Is Justified
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
SITC Is Only 33 Days Away: Abstract Titles Released
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - ESMO 2019 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Subsequent Therapy Imbalances Obviate T-VEC + Yervoy ESMO Data Extrapolations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Will GALV plus GM-CSF Be a Game- Changer? Initiating at Buy, $20 PT
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T